Error in the Exclusion of Participants From Analysis in the ACTIV-6 Platform Randomized Clinical Trial

This article reported the findings of the double-blind Accelera ting COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6) platform randomized clinical trial of 1206 US adults with COVID-19 who received a targeted dose of 600 μg/kg of ivermectin or placebo for 6 days during February 2022 to July 2022. The primary outcome was time to sustained recovery, de fined as at least 3 consecutive days without symptoms. As we reported, “the median time to sustained recovery was 11 days in the ivermectin group and 11 days in the placebo group. In this largely vaccinated (84%) population, the posterior probability that ivermectin reduced symptom duration by mor e than 1 day was less than 0.1%.”
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research